Reuters logo
1 个月前
BRIEF-Coherus Biosciences says projected filing timing for CHS-1420 biologics license application pushed to first half of 2018
2017年6月26日 / 晚上8点38分 / 1 个月前

BRIEF-Coherus Biosciences says projected filing timing for CHS-1420 biologics license application pushed to first half of 2018

1 分钟阅读

June 26 (Reuters) - Coherus Biosciences Inc

* Coherus Biosciences - determined it is prudent to put into place alternative fill & finish vendor to support co's adalimumab biosimilar candidate chs-1420's bla filing

* Coherus Biosciences Inc - the change will move projected filing timing for chs-1420 biologics license application to first half of 2018 - Sec Filing Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below